Sensei Biotherapeutics has new Phase 1/2 head/neck carcinoma data at ASCO

 Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –

– One deep (71% tumor reduction) and durable (11 months) partial response and two longstanding (8 and 10 months) stable diseases observed in patients with no response to prior PD-1 blockade –

– Data show potential of company’s proprietary ImmunoPhage™ platform to expand and improve current oncology treatments −

Data from Phase 1/2 Trial of SNS-301 SSCCHN As of April 14, 2021

Data highlighted today are part of a poster (#6029), titled: “Update on Safety and Efficacy of a Phase 1/2 Trial of SNS-301 and Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck.” The abstract and related poster can be downloaded from the ASCO Meeting Library.

https://finance.yahoo.com/news/sensei-biotherapeutics-announces-clinical-data-210300950.html